However, METTL13 expression did not significantly differ between HER2-negative and HER2-positive breast cancers (Fig. S1B), and SETDB1 is a well-known potential modulator of breast cancer metastasis 36. This evidence concerns the gene ERBB2 and breast carcinoma.